The Journal of dermatological treatment最新文献_第3页

Nomogram for predicting risk of relapse following complete remission in pemphigus patients. 预测天疱疮患者完全缓解后复发风险的Nomogram。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-02-25 DOI: 10.1080/09546634.2026.2633065

Xuan Long, Nam Yiu, Xueting Yang, Wenyu Zhou, Miao Yang, Guiying Zhang

{"title":"Nomogram for predicting risk of relapse following complete remission in pemphigus patients.","authors":"Xuan Long, Nam Yiu, Xueting Yang, Wenyu Zhou, Miao Yang, Guiying Zhang","doi":"10.1080/09546634.2026.2633065","DOIUrl":"https://doi.org/10.1080/09546634.2026.2633065","url":null,"abstract":"Background: Pemphigus is a recurrent and potentially life-threatening autoimmune bullous disease. This study aimed to develop a nomogram to predict relapse risk in pemphigus patients after complete remission (CR).Methods: We retrospectively analyzed 110 pemphigus patients who achieved CR between 2021 and 2023 and were followed for at least 12 months. Independent predictors of relapse were identified using univariate and multivariate Cox regression analyses and incorporated into a nomogram. Model performance was evaluated using calibration curves, receiver operating characteristic (ROC) analysis, and decision curve analysis (DCA).Results: During follow-up, 41.8% of patients experienced relapse. Multivariate analysis identified anemia, hypercholesterolemia, previous relapse history, elevated desmoglein (Dsg) antibody levels, and discontinuation of therapy after CR as independent risk factors. The nomogram demonstrated good discrimination with a concordance index of 0.726 (95% CI, 0.659-0.793). The AUCs for predicting relapse at 6, 12, and 18 months after achieving CR were 0.771, 0.853, and 0.811, respectively. DCA supported the clinical utility of the model, and survival analysis effectively stratified patients into high- and low-risk groups.Conclusion: This nomogram may serve as a practical tool for identifying pemphigus patients at high risk of relapse after CR.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2633065"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence. 奈莫单抗治疗特应性皮炎和结节性痒疹以外的慢性瘙痒：新证据的系统回顾和综合。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-01-08 DOI: 10.1080/09546634.2026.2612882

Mohammed Shanshal, Aarthy Uthayakumar

{"title":"Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence.","authors":"Mohammed Shanshal, Aarthy Uthayakumar","doi":"10.1080/09546634.2026.2612882","DOIUrl":"10.1080/09546634.2026.2612882","url":null,"abstract":"Background: Nemolizumab, an anti-IL-31 receptor A antibody, is licensed for atopic dermatitis and prurigo nodularis; its role in other chronic pruritus (CP) syndromes is uncertain.Objective: To synthesize efficacy, safety and strength of evidence for nemolizumab in CP beyond these indications. Methods: We conducted a PROSPERO-registered systematic review (CRD420251207054) of databases and trial registries to November 2025 for nemolizumab studies in CP outside AD/PN. Eligible reports were extracted and patients grouped as systemic, neurologic/neurogenic, dermatologic (non-AD) or primary CP/CP of unknown origin.Results: Seventeen reports (one randomized trial, two cohorts, 14 case series/reports) describing 114 patients were included. In chronic kidney disease-associated pruritus, a phase II hemodialysis trial showed modest, statistically uncertain benefit versus placebo, contrasting with rapid, near-complete relief in dialysis and cholestatic case reports. Uncontrolled data in neuropathic itch/pain syndromes, non-AD inflammatory and papular dermatoses (notably amyloidosis and perforating disorders) and long-standing primary CP/CPUO described complete itch clearance. Across indications, nemolizumab was well tolerated, but certainty was low for CKD-aP and very low for other groups.Conclusions: Nemolizumab shows plausible antipruritic activity across CP phenotypes, yet the evidence base remains fragile; these signals justify cautious experimental use and prioritize etiology-specific IL-31 receptor blockade trials beyond AD/PN.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2612882"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145936824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patients' and clinicians' perspectives on telemedicine to monitor patients on systemic treatment for psoriasis or atopic dermatitis - a mixed methods study. 患者和临床医生对远程医疗监测银屑病或特应性皮炎患者全身治疗的观点——一项混合方法研究

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-08-10 DOI: 10.1080/09546634.2026.2703354

Nikki F T Henckens, Marta E Pawlak, Sophie A C Wanten, Ying C Weng, Ilse V Ee, Bernd W M Arents, Leonard Witkamp, Marjolein S de Bruin-Weller, Ewout M Baerveldt, Marieke M B Seyger, Elke M G J de Jong, Wynanda A van Enst, Juul M P A van den Reek

{"title":"Patients' and clinicians' perspectives on telemedicine to monitor patients on systemic treatment for psoriasis or atopic dermatitis - a mixed methods study.","authors":"Nikki F T Henckens, Marta E Pawlak, Sophie A C Wanten, Ying C Weng, Ilse V Ee, Bernd W M Arents, Leonard Witkamp, Marjolein S de Bruin-Weller, Ewout M Baerveldt, Marieke M B Seyger, Elke M G J de Jong, Wynanda A van Enst, Juul M P A van den Reek","doi":"10.1080/09546634.2026.2703354","DOIUrl":"https://doi.org/10.1080/09546634.2026.2703354","url":null,"abstract":"Background: For patients with stable psoriasis or atopic dermatitis (AD) receiving systemic treatment, telemedicine may offer a viable alternative to in-person consultations. However, perspectives of these patients and dermatological care providers (DCPs) regarding telemedicine are underexplored, yet essential for successful implementation.Objectives: To explore experiences, preferences, and perspectives of patients and DCPs regarding telemedicine for patients with psoriasis or AD on systemic treatment.Methods: A mixed-methods study was conducted using surveys and semi-structured interviews with patients and DCPs.Results: Surveys were completed by 162 patients and 152 DCPs, and interviews by 12 patients and 5 DCPs. Both groups expressed positive attitudes toward telemedicine, provided stable disease. Patients valued telemedicine for practical benefits, including time/cost savings, but emphasized the importance of an established relationship with DCPs before its initiation. DCPs identified key enablers including improved ICT-support, user-friendly systems, and adequate reimbursement. The majority of patients and DCPs supported telemedicine implementation, with telephonic consultations as preferred method. Many DCPs believed ≥50% of consultations could be conducted through telemedicine. Additionally, telemedicine leads to substantial CO2-equivalent emission reduction.Conclusion: Patients and DCPs supported further implementation of telemedicine in patients with stable psoriasis or AD on systemic treatment and identified practical, financial and societal facilitators.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2703354"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of redness in rosacea with potassium-titanyl-phosphate (KTP) 532 nm laser with and without topical 1% ivermectin cream: a randomized split-face trial. 磷酸钾-钛基（KTP） 532 nm激光治疗酒渣鼻红肿，加或不加局部1%伊维菌素乳膏：一项随机裂面试验。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-03-04 DOI: 10.1080/09546634.2026.2635882

Kristine Heidemeyer, Simone Cazzaniga, Alexandra Junge, Mathias Lehmann, S Morteza Seyed Jafari, Nikhil Yawalkar, Laurence Feldmeyer, Simon Bossart

{"title":"Treatment of redness in rosacea with potassium-titanyl-phosphate (KTP) 532 nm laser with and without topical 1% ivermectin cream: a randomized split-face trial.","authors":"Kristine Heidemeyer, Simone Cazzaniga, Alexandra Junge, Mathias Lehmann, S Morteza Seyed Jafari, Nikhil Yawalkar, Laurence Feldmeyer, Simon Bossart","doi":"10.1080/09546634.2026.2635882","DOIUrl":"10.1080/09546634.2026.2635882","url":null,"abstract":"Objective: Facial erythema and telangiectasia in rosacea are commonly treated with vascular lasers. Combination with ivermectin 1% cream, may enhance outcomes when combined with laser therapy. This study assesses whether topical ivermectin improves the efficacy of Potassium Titanyl Phosphate (KTP) 532 nm laser for facial erythema in rosacea.Methods: This is a randomized, evaluator-blinded, split-face study. 24 patients with rosacea received four KTP laser sessions; one facial side was additionally treated daily with ivermectin 1% cream. The primary outcome was the change in Normalized Erythema Index (NEI). Secondary measures included Skin Redness Index (SRI), Clinical Erythema Assessment, Physician Global Assessment, telangiectasia score, inflammatory lesion counts, patient satisfaction, and safety.Results: At week 16, the combination side showed a significantly greater NEI reduction than laser alone (ΔNEI%: 16.6 vs 5.3; p = 0.04). No significant differences were observed in SRI, and all other scores. However, papule reduction across visits was significantly greater with ivermectin (p = 0.02). Both treatments were well tolerated, with no serious adverse events.Conclusion: KTP laser effectively reduces erythema and inflammatory lesions; adjunctive ivermectin may further enhance papulopustular lesions. The combination is well tolerated, suggesting a potential adjunctive role for topical ivermectin in laser-based rosacea therapy.Clinical trial register: clinicalTrials.gov (NCT06033352).","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2635882"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147350191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy and safety of oral azithromycin versus doxycycline in moderate-to-severe Acne vulgaris: a systematic review and meta-analysis. 口服阿奇霉素与强力霉素治疗中重度寻常痤疮的疗效和安全性比较：一项系统综述和荟萃分析。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-05-05 DOI: 10.1080/09546634.2026.2648406

Asia Batool, Muhammad Sharjeel Abbas, Makhzan Ali Akbar, Meer Murtaza, Fakhar E Mahin, Umair Ali, Abu-Bakr Ahmed, Muhammad Huzaifa Khattak, Menahil Fazal, Zoona Maryam, Raafay Yaqoob, Joao Victor Silva Correia, Hasibullah Aminpoor

{"title":"Comparative efficacy and safety of oral azithromycin versus doxycycline in moderate-to-severe Acne vulgaris: a systematic review and meta-analysis.","authors":"Asia Batool, Muhammad Sharjeel Abbas, Makhzan Ali Akbar, Meer Murtaza, Fakhar E Mahin, Umair Ali, Abu-Bakr Ahmed, Muhammad Huzaifa Khattak, Menahil Fazal, Zoona Maryam, Raafay Yaqoob, Joao Victor Silva Correia, Hasibullah Aminpoor","doi":"10.1080/09546634.2026.2648406","DOIUrl":"10.1080/09546634.2026.2648406","url":null,"abstract":"Background: Acne vulgaris is a chronic inflammatory disease and is one of the leading causes of dermatological morbidities among young adults. Doxycycline is widely recommended as first-line therapy for moderate to severe acne; however, its use is limited.Objective: To systematically compare the efficacy and safety of oral azithromycin pulse therapy versus doxycycline in patients with moderate to severe acne vulgaris.Methods: This systematic review and meta-analysis followed PRISMA guidelines. A comprehensive literature search on different databases was performed. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were pooled using random-effects models based on heterogeneity.Results: A total of 23 comparative studies comprising 2,769 patients were included. Pooled analysis demonstrated a statistically significant improvement in global acne severity favoring azithromycin (GAGS reduction: MD 1.81; 95% CI 1.28-2.34; I2 = 0%). Azithromycin achieved a significantly greater reduction in non-inflammatory lesion counts (MD -7.56; 95% CI -14.33 to -0.79). No significant differences were observed in inflammatory lesion reduction (MD 1.08; 95% CI -0.03 to 2.18).Conclusion: Oral azithromycin pulse therapy appears to have similar efficacy, better tolerability, and fewer side effects as compared to doxycycline.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2648406"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147848318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of oral finasteride versus dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran. 口服非那雄胺与度他雄胺治疗男性中度至重度雄激素性脱发的疗效和安全性：基于毛镜和实验室结果：伊朗的临床比较

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-07-17 DOI: 10.1080/09546634.2025.2583849

Nazila Poostiyan, Zahra Nikyar, Reza Makhmali, Mohsen Hosseini, Zabihollah Shahmoradi

{"title":"Efficacy and safety of oral finasteride versus dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran.","authors":"Nazila Poostiyan, Zahra Nikyar, Reza Makhmali, Mohsen Hosseini, Zabihollah Shahmoradi","doi":"10.1080/09546634.2025.2583849","DOIUrl":"10.1080/09546634.2025.2583849","url":null,"abstract":"Background: Androgenetic alopecia (AGA) is the most common type of hair loss in men. Finasteride and dutasteride are oral 5-alpha-reductase inhibitors. This study compared their efficacy and safety in Iranian men with moderate to severe AGA.Methods: This randomized single-blind clinical trial included 46 men aged 20-50 years. Patients received finasteride 1 mg daily or dutasteride 0.5 mg daily for 24 weeks. Hair density and thickness were measured by trichoscopy and photographs. Satisfaction was recorded with a visual analog scale (VAS). Adverse effects were documented.Results: Both groups improved in hair growth after 24 weeks with no significant difference. Serum PSA fell in the dutasteride group from 0.63 ± 0.18 to 0.42 ± 0.22 (p < 0.001). No significant change appeared in the finasteride group. Dutasteride produced greater PSA reduction than finasteride (B = 0.17, p < 0.01). Age had no effect on PSA (p = 0.58). VAS scores showed no difference. Safety profiles were similar. Sexual side effects were most common, with erectile dysfunction more frequent in the finasteride group. No serious events occurred.Conclusion: Finasteride and dutasteride improved hair density with similar safety. Dutasteride caused stronger PSA reduction, suggesting more potent 5-alpha-reductase inhibition.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2583849"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148475216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Commentary on benefit-risk profile comparison between dupilumab and upadacitinib: a structured benefit-risk assessment of the heads up trial. dupilumab和upadacitinib的获益-风险比较评论：heads up试验的结构化获益-风险评估。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-09-28 DOI: 10.1080/09546634.2026.2735534

Ercan Yılmaz, Nezihe Koker Özer, Erdem Topal

引用次数: 0

Quality of life and patient-reported side effects of low-dose oral minoxidil in treating female pattern hair loss. 低剂量口服米诺地尔治疗女性型脱发的生活质量和患者报告的副作用。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-02-25 DOI: 10.1080/09546634.2026.2633066

Divija Sharma, Lillian Mo, Deep Patel, Austin Piontkowski, Candice Medina, Kelly Hawkins, Neda Shokrian, Benjamin Ungar

{"title":"Quality of life and patient-reported side effects of low-dose oral minoxidil in treating female pattern hair loss.","authors":"Divija Sharma, Lillian Mo, Deep Patel, Austin Piontkowski, Candice Medina, Kelly Hawkins, Neda Shokrian, Benjamin Ungar","doi":"10.1080/09546634.2026.2633066","DOIUrl":"10.1080/09546634.2026.2633066","url":null,"abstract":"Female pattern hair loss (FPHL) significantly affects women's well-being and quality of life (QoL), and low-dose oral minoxidil (LDOM) has increasingly gained attention as a convenient and effective treatment option. Although hypertrichosis is reported more often with LDOM than with topical formulations, patient perceptions and tolerance of this side effect remain poorly understood. We conducted a telephone survey at a single institution among women with FPHL currently taking or previously treated with LDOM for at least one month to evaluate treatment effectiveness, QoL, and side effect burden using the Women's Androgenetic Alopecia Quality of Life Questionnaire (WAA-QOL). Among 102 participants, the median duration of LDOM use was 12 months. Hair loss severity improved from a median score of 7 to 4 on a 10-point scale. Unwanted hair growth occurred in 71.6% of patients, most commonly on the face, arms, and legs; however, 93.2% did not consider it a reason to discontinue treatment, and most cases were mild or moderate. WAA-QOL scores improved significantly from baseline (67 to 39, p<0.001), with no predictors of unwanted hair growth identified. Overall, patients experienced clinical and QoL improvements, supporting a favorable patient-centered profile for LDOM.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2633066"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147313800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study. omalizumab治疗中国青少年慢性自发性荨麻疹的安全性和有效性：一项真实世界、前瞻性、多中心研究

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-07-13 DOI: 10.1080/09546634.2026.2694909

Yu Wang, Chengzhi Lv, Bin Yang, Zigang Xu, Lin Ma, Lixiong Gu, Zhiming Li, Niu Xiang, Xiaoyong Man, Juan Su, Liming Wu, Min Shu, Sirao Wang, Yujia Song, Yumeng Ren, Yuling Shi

{"title":"Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study.","authors":"Yu Wang, Chengzhi Lv, Bin Yang, Zigang Xu, Lin Ma, Lixiong Gu, Zhiming Li, Niu Xiang, Xiaoyong Man, Juan Su, Liming Wu, Min Shu, Sirao Wang, Yujia Song, Yumeng Ren, Yuling Shi","doi":"10.1080/09546634.2026.2694909","DOIUrl":"10.1080/09546634.2026.2694909","url":null,"abstract":"Objective: Chronic spontaneous urticaria (CSU) is a burdensome skin disorder that may remain inadequately controlled with standard H1 antihistamines (H1 AHs). Evidence on adolescents with CSU is limited. This 16-week study evaluated the safety and effectiveness of omalizumab in Chinese adolescents (≥12 to <18 years) with CSU who remained symptomatic despite H1 AH treatment (treatment period: 12 weeks; safety follow-up: 4 weeks).Methods: Safety assessments and routine clinical evaluations were performed. Effectiveness and quality of life were analyzed using the weekly urticaria activity score (UAS7), weekly itch severity score (ISS7), Urticaria Control Test (UCT), and Children's Dermatology Life Quality Index (CDLQI).Results: All 55 enrolled participants completed the study. Twenty-two participants (40.0%) experienced ≥1 treatment-emergent adverse event (TEAE). No serious adverse events, adverse events of special interest, deaths, or TEAEs leading to treatment discontinuation occurred. At Week 12, changes from baseline in ISS7 and UAS7 were -11.73 and -25.07, respectively; 70.9% participants achieved well-controlled CSU (UCT ≥ 12). The absolute mean change in CDLQI was -9.7 (relative improvement at Week 12: -81.5%).Conclusions: Omalizumab demonstrated a favorable safety profile and clinically meaningful effectiveness in Chinese adolescents with CSU who remained symptomatic despite H1 AH therapy and is a valuable option for this underrepresented population.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2694909"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148431850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Physical activity as a potential nonpharmacologic strategy to prevent seborrheic dermatitis: a cohort study in the UK biobank. 体育活动作为预防脂溢性皮炎的潜在非药物策略：英国生物银行的一项队列研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2026-12-01 Epub Date: 2026-03-30 DOI: 10.1080/09546634.2026.2646001

Ziye Yang, Tong Zhang, Tongtong Zhang, Jiachen Liu, Rui Mao, Li Yang

{"title":"Physical activity as a potential nonpharmacologic strategy to prevent seborrheic dermatitis: a cohort study in the UK biobank.","authors":"Ziye Yang, Tong Zhang, Tongtong Zhang, Jiachen Liu, Rui Mao, Li Yang","doi":"10.1080/09546634.2026.2646001","DOIUrl":"10.1080/09546634.2026.2646001","url":null,"abstract":"Background: Seborrheic dermatitis (SD) is a chronic inflammatory skin disease with limited long-term treatment options. The association between physical activity and incident SD, as well as the potential mediating role of depressive symptoms, remains unclear.Objective: To investigate the association between physical activity and incident SD and to assess whether depressive symptoms mediate this relationship.Methods: Data from 396,903 participants in the UK Biobank were analyzed. Cox proportional hazards models were used to examine the association between physical activity and incident SD. Regression-based mediation analyses were performed to quantify the extent to which depressive symptoms mediated this association.Results: Physical activity above the recommended minimum (≥600 MET-min/week) was associated with a lower risk of incident SD. The greatest risk reduction was observed at 3-5 times the recommended level (1,800-3,000 MET-min/week; HR 0.80, 95% CI 0.71-0.90). Participants meeting criteria for healthy physical activity had a 28% lower risk of incident SD (HR 0.72, 95% CI 0.64-0.81). Mediation analyses showed that 17% of the protective association was explained by reduced depressive symptoms (indirect HR 0.83, 95% CI 0.77-0.88), while 16% was attributable to the direct effect of physical activity (direct HR 0.84, 95% CI 0.77-0.93).Conclusions: Physical activity may serve as a non-pharmacologic strategy for the prevention of SD, partly through alleviating depressive symptoms. The maximal benefit was observed at 3-5 times the recommended minimum activity level.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2646001"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147577235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0